- Core and Additional Components Influenza, an important cause of morbidity and mortality, and influenza vaccination are key components of influenza prevention. The effectiveness of influenza vaccine varies from year to year, and it can vary by virus subtype, age group, product type, population characteristics, and antigenic match. Annual assessment of clinical vaccine effectiveness is therefore needed to evaluate the impact of current vaccine recommendations and policies, understand the relationship between antigenic changes in viruses and clinical protection, and prepare for vaccine assessment during a pandemic. Interim, mid-season estimates of vaccine effectiveness are useful for public health agencies and physicians.
The first Aim of the project is to estimate the effectiveness of influenza vaccine for preventing medically-attended, laboratory confirmed influenza illness in a defined population cohort of adults and children. Patients who seek outpatient care for acute respiratory illness will be recruited during the influenza season. Patients with cough and illness duration ?7 days will be eligible. After informed consent, nose and throat swabs will be tested for influenza A and B using a nucleic acid amplification test (RT- PCR). Samples will be provided to CDC for antigenic characterization and other tests as appropriate. Influenza immunization status will be determined by a validated immunization registry. Vaccine effectiveness will be calculated using the test negative design where cases include participants with RT-PCR confirmed influenza and controls include study participants with noninfluenza respiratory illness (negative RT-PCR). Data will be provided to CDC for combined analyses with other participating sites, including mid-season data for interim analysis of effectiveness. When possible, separate estimates of vaccine effectiveness will be calculated for different age groups, influenza subtypes, and for different vaccine products.
The second Aim i s to evaluate the disease burden due to RSV during the last three seasons of the project. Participant samples will be tested for RSV using RT-PCR, and the incidence of medically attended RSV will be estimated.
The third Aim i s to serve as an emergency response resource for CDC pandemic studies of vaccination and antivirals. This will include pilot studies to prepare for a pandemic.

Public Health Relevance

- Core and Additional Components Influenza vaccine effectiveness can vary from year to year, and studies to measure vaccine effectiveness provide important information for public health agencies, regulatory agencies, physicians, and the general public. For this project, we will enroll and test patients with acute respiratory illness to estimate influenza vaccine effectiveness for different age groups, virus types, and vaccine products. We will also conduct pilot studies to prepare for a future influenza pandemic.

Agency
National Institute of Health (NIH)
Institute
National Center for Immunication and Respiratory Diseases (NCIRD)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01IP001038-02
Application #
9323277
Study Section
Special Emphasis Panel (ZIP1)
Program Officer
Loveys, Deborah
Project Start
2016-08-01
Project End
2021-07-31
Budget Start
2017-08-01
Budget End
2018-07-31
Support Year
2
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Marshfield Clinic Research Foundation
Department
Type
DUNS #
074776030
City
Marshfield
State
WI
Country
United States
Zip Code
54449
Russell, Kate; Chung, Jessie R; Monto, Arnold S et al. (2018) Influenza vaccine effectiveness in older adults compared with younger adults over five seasons. Vaccine 36:1272-1278
Shang, Mei; Chung, Jessie R; Jackson, Michael L et al. (2018) Influenza vaccine effectiveness among patients with high-risk medical conditions in the United States, 2012-2016. Vaccine 36:8047-8053
Flannery, Brendan; Smith, Catherine; Garten, Rebecca J et al. (2018) Influence of Birth Cohort on Effectiveness of 2015-2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1) Virus in the United States. J Infect Dis 218:189-196
Florek, Nicholas W; Campos, Luiza M; Braun, Katarina M et al. (2018) An updated influenza A(H3N2) vaccine generates limited antibody responses to previously encountered antigens in children. Vaccine 36:758-764
King, Jennifer P; McLean, Huong Q; Meece, Jennifer K et al. (2018) Vaccine failure and serologic response to live attenuated and inactivated influenza vaccines in children during the 2013-2014 season. Vaccine 36:1214-1219
Stewart, Rebekah J; Flannery, Brendan; Chung, Jessie R et al. (2018) Influenza Antiviral Prescribing for Outpatients With an Acute Respiratory Illness and at High Risk for Influenza-Associated Complications During 5 Influenza Seasons-United States, 2011-2016. Clin Infect Dis 66:1035-1041
Jackson, Michael L; Phillips, C Hallie; Benoit, Joyce et al. (2018) Burden of medically attended influenza infection and cases averted by vaccination - United States, 2013/14 through 2015/16 influenza seasons. Vaccine 36:467-472
Ferdinands, Jill M; Fry, Alicia M; Reynolds, Sue et al. (2017) Intraseason waning of influenza vaccine protection: Evidence from the US Influenza Vaccine Effectiveness Network, 2011-12 through 2014-15. Clin Infect Dis 64:544-550
Jackson, Michael L; Chung, Jessie R; Jackson, Lisa A et al. (2017) Influenza Vaccine Effectiveness in the United States during the 2015-2016 Season. N Engl J Med 377:534-543
Flannery, Brendan; Chung, Jessie R; Thaker, Swathi N et al. (2017) Interim Estimates of 2016-17 Seasonal Influenza Vaccine Effectiveness - United States, February 2017. MMWR Morb Mortal Wkly Rep 66:167-171

Showing the most recent 10 out of 13 publications